BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

iSonea Limited Files FDA Submission for Over-the-Counter SonoSentry™


10/3/2012 11:29:43 AM

SEVERNA PARK, Md., Oct. 3, 2012 /PRNewswire/ -- Medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAD) today announced that it submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) on Thursday, September 27, to market the SonoSentry, a rebranded non-prescription version of its personal Wheezometer, over the counter to consumers.

(Logo: http://photos.prnewswire.com/prnh/20120831/NE65948LOGO)

Like the Wheezometer, the SonoSentry measures a person's wheeze, a principal symptom of asthma. Using iSonea's proprietary Acoustic Respiratory Monitoring (ARM) technology, SonoSentry calculates a WheezeRATE, the percentage of breathing time spent wheezing.

"Having the SonoSentry available over-the-counter will make our unique ARM technology more broadly accessible," said Michael J. Thomas, CEO of iSonea Ltd. "The SonoSentry provides an objective measurement of wheezing and can help asthmatics to monitor this symptom more accurately and easily."

Once the filing is officially accepted by the agency, the typical review period is 90 days.

About iSonea Limited

iSonea Limited (ASX: ISN; OTCQX: ISOAD) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring (ARM) technology with its AsthmaSense mobile applications, iSonea is turning smartphones into medical devicesenabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. For more information, please visit www.SoundAsthma.com.

Media Inquiries:


Mr. Michael Thomas

Jon Siegal or Jennifer Netzband

Chief Executive Officer

Schwartz MSL Boston

iSonea Limited

+1 781-684-0770

+1 410-777-5251

iSonea@schwartzmsl.com

mthomas@iSoneaMed.com

www.schwartzmsl.com

website: www.iSoneaMed.com



Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

SOURCE iSonea Limited


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->